JP2023539589A - Ｅｇｆｒ変異を有する非小細胞肺がんの治療 - Google Patents

Ｅｇｆｒ変異を有する非小細胞肺がんの治療 Download PDF

Info

Publication number
JP2023539589A
JP2023539589A JP2023513309A JP2023513309A JP2023539589A JP 2023539589 A JP2023539589 A JP 2023539589A JP 2023513309 A JP2023513309 A JP 2023513309A JP 2023513309 A JP2023513309 A JP 2023513309A JP 2023539589 A JP2023539589 A JP 2023539589A
Authority
JP
Japan
Prior art keywords
egfr
cancer
seq
amivantamab
shows
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539589A5 (cg-RX-API-DMAC10.html
Inventor
ノブロック，ローランド
ムーアズ，シェリ
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2023539589A publication Critical patent/JP2023539589A/ja
Publication of JP2023539589A5 publication Critical patent/JP2023539589A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2023513309A 2020-08-25 2021-08-25 Ｅｇｆｒ変異を有する非小細胞肺がんの治療 Pending JP2023539589A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063069748P 2020-08-25 2020-08-25
US63/069,748 2020-08-25
PCT/IB2021/057794 WO2022043895A2 (en) 2020-08-25 2021-08-25 Treatment of non-small lung cancer with egfr mutations

Publications (2)

Publication Number Publication Date
JP2023539589A true JP2023539589A (ja) 2023-09-15
JP2023539589A5 JP2023539589A5 (cg-RX-API-DMAC10.html) 2024-09-02

Family

ID=80352814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513309A Pending JP2023539589A (ja) 2020-08-25 2021-08-25 Ｅｇｆｒ変異を有する非小細胞肺がんの治療

Country Status (11)

Country Link
US (2) US12528869B2 (cg-RX-API-DMAC10.html)
EP (1) EP4204455A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023539589A (cg-RX-API-DMAC10.html)
KR (1) KR20230053686A (cg-RX-API-DMAC10.html)
CN (1) CN116194141A (cg-RX-API-DMAC10.html)
AU (1) AU2021330539A1 (cg-RX-API-DMAC10.html)
CA (1) CA3192922A1 (cg-RX-API-DMAC10.html)
IL (1) IL300854A (cg-RX-API-DMAC10.html)
JO (1) JOP20230039A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023002362A (cg-RX-API-DMAC10.html)
WO (1) WO2022043895A2 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230174677A1 (en) * 2021-11-16 2023-06-08 Janssen Biotech, Inc. Use of Approved Bispecific EGFR and Met Specific Antibody Drug Product to Treat Non-Small Cell Lung Cancer (NSCLCL)
CN119790073A (zh) * 2022-06-30 2025-04-08 詹森生物科技公司 使用抗EGFR/抗Met抗体治疗胃癌或食道癌
WO2024108193A2 (en) * 2022-11-18 2024-05-23 Epibiologics, Inc. Degradation of cmet using a bispecific binding agent
CN116284335A (zh) * 2023-03-17 2023-06-23 云南中医药大学 Egfr基因突变体的检测方法及应用
WO2025158277A1 (en) * 2024-01-22 2025-07-31 Janssen Biotech, Inc. Use of amivantamab to treat head and neck cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
AU2005250484B2 (en) 2004-06-04 2011-08-11 Genentech, Inc. EGFR mutations
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
EP3904391B1 (en) 2010-03-10 2024-07-10 Genmab A/S Monoclonal antibodies against c-met
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CA2832971C (en) 2011-04-15 2016-04-12 Esco Corporation Replaceable wear parts for an earth-working roll
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
EP3029067A1 (en) 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Use of blocking-reagents for reducing unspecific T cell-activation
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
BR112019010020A2 (pt) 2016-11-17 2019-08-20 Univ Texas compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
WO2020102647A1 (en) 2018-11-15 2020-05-22 Invenra Inc. Multivalent receptor-clustering agonist antibody constructs and antigen binding proteins
MX2021010265A (es) 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
IL305700A (en) 2021-03-09 2023-11-01 Janssen Biotech Inc Treatment of cancers lacking EFGR-activating mutations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-S", NCT02609776, CLINICALTRIALS.GOV, vol. retrieved on 2026.05.24, JPN6026021780, 13 August 2020 (2020-08-13), pages retrieved from the internet, ISSN: 0005874601 *
CANCER DISCOV, vol. 10 (8), JPN6025036569, 3 August 2020 (2020-08-03), pages 1194 - 1209, ISSN: 0005874600 *
CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, vol. Volume 148, 102906, JPN6025036570, April 2020 (2020-04-01), pages 1 - 13, ISSN: 0005874602 *

Also Published As

Publication number Publication date
JOP20230039A1 (ar) 2023-02-23
WO2022043895A8 (en) 2023-03-09
CA3192922A1 (en) 2022-03-03
AU2021330539A1 (en) 2023-05-04
US20260070993A1 (en) 2026-03-12
AU2021330539A9 (en) 2023-07-13
EP4204455A4 (en) 2024-10-16
MX2023002362A (es) 2023-05-19
WO2022043895A2 (en) 2022-03-03
US12528869B2 (en) 2026-01-20
WO2022043895A3 (en) 2022-06-09
EP4204455A2 (en) 2023-07-05
IL300854A (en) 2023-04-01
KR20230053686A (ko) 2023-04-21
CN116194141A (zh) 2023-05-30
US20220064306A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
US20260125480A1 (en) Bispecific EGFR/C-Met Antibodies
US12528869B2 (en) Treatment of non-small cell lung cancer with EGFR mutations
JP2024153659A (ja) 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化
US12215160B2 (en) Treatment of patients having c-met exon 14 skipping mutations
US20230183360A1 (en) Use of Amivantamab to Treat Colorectal Cancer
CN110636861A (zh) 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法
IL324821A (en) Methods for treating non-small cell lung cancer (NSCLC)
EP4476255A1 (en) Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
US20220298248A1 (en) Treatment of Cancers Lacking EGFR- Activating Mutations
EA050561B1 (ru) Лечение немелкоклеточного рака легкого с мутациями egfr
US20240228634A1 (en) Treatment of Cancers Lacking EGFR- Activating Mutations
HK40116078A (en) Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
WO2026038160A1 (en) Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
EA050376B1 (ru) ЛЕЧЕНИЕ ПАЦИЕНТОВ, ИМЕЮЩИХ МУТАЦИИ, ВЫЗЫВАЮЩИЕ ПРОПУСК ЭКЗОНА 14 В c-Met
HK40066269A (en) Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602